Bioheart to Present at Cell Therapy for Cardiovascular Disease
Conference in New York
SUNRISE, Fla., Jan. 7, 2013 /PRNewswire/ -- Bioheart, Inc.
(BHRT.QB) will present an update on 12 years of clinical data on
MyoCell for treating heart failure at the 8th Annual
Conference on Cell Therapy for Cardiovascular Disease January 23-25th, 2013 @ Columbia University Medical Center -
http://celltherapy.crf.org/register.html - Course Director,
Warren Sherman, M.D.
(Logo:
http://photos.prnewswire.com/prnh/20130107/FL37699LOGO )
Howard J. Leonhardt, Founder and
Chief Technology Officer of Bioheart, will present data from
clinical trials sponsored by the company since 2001.
In Phase II/III clinical trials stage in the U.S. for muscle
stem cells for treating advanced heart failure, Bioheart's MyoCell
is believed to be the only cell type able to create new contractile
muscle in heart scar tissue. Phase II/III Part I interim
results demonstrated 95.7 meters improvement in exercise capacity
in Bioheart MyoCell patients over placebo (-4 meters) in a double
blind randomized study. This compares to -4 meters for CHF
drugs, 16 meters for CRT pacers, 53 meters for cardiac stem cells,
52 meters for adipose derived cells and 10 meters allogeneic bone
marrow derived cells.
Leonhardt will also provide a look at new generation
improvements brought forward to enhance cell transplantation by
Bioheart which include: SDF-1 gene transfection, electrical
stimulation – see http://www.myostimpacers.com, repeat injections,
and nutrient hydrogel.
Founded in 1999, Bioheart is one of the original cell therapy
companies. Since that time, more than 400 heart failure
patients have been enrolled in various myoblast therapy clinical
trials worldwide. 84% percent of Bioheart MyoCell treated
patients have improved while only 16% have worsened. In
placebo and control groups 69% of patients have worsened.
130 more patients are needed to complete the randomized, double
blinded, placebo controlled MARVEL trial. MyoCell is a
muscle-derived stem cell therapy designed to populate regions of
scar tissue within a patient's heart with new living cells for the
intended purpose of improving cardiac function and quality of life
in chronic heart failure patients.
About Bioheart, Inc.
Bioheart is committed to maintaining its leading position within
the cardiovascular sector of the cell technology industry
delivering cell therapies and biologics that help address
congestive heart failure, lower limb ischemia, chronic heart
ischemia, acute myocardial infarctions and other issues.
Bioheart's goals are to cause damaged tissue to be regenerated,
when possible, and to improve a patient's quality of life and
reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery,
development and, subject to regulatory approval, commercialization
of autologous cell therapies for the treatment of chronic and acute
heart damage and peripheral vascular disease. Its leading product,
MyoCell, is a clinical muscle-derived cell therapy designed to
populate regions of scar tissue within a patient's heart with new
living cells for the purpose of improving cardiac function in
chronic heart failure patients. For more information on Bioheart,
visit www.bioheartinc.com, or visit us on Facebook: Bioheart and
Twitter @BioheartInc.
Forward-Looking Statements: Except for historical matters
contained herein, statements made in this press release are
forward-looking statements. Without limiting the generality of the
foregoing, words such as "may," "will," "to," "plan," "expect,"
"believe," "anticipate," "intend," "could," "would," "estimate," or
"continue" or the negative other variations thereof or comparable
terminology are intended to identify forward-looking
statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Also, forward-looking statements
represent our management's beliefs and assumptions only as of the
date hereof. Except as required by law, we assume no obligation to
update these forward-looking statements publicly, or to update the
reasons actual results could differ materially from those
anticipated in these forward-looking statements, even if new
information becomes available in the future.
The Company is subject to the risks and uncertainties described
in its filings with the Securities and Exchange Commission,
including the section entitled "Risk Factors" in its Annual Report
on Form 10-K for the year ended December 31,
2011, and its Quarterly Report on Form 10-Q for the quarter
ended September 30, 2012.
This press release distribution was issued via PR
Syndication.
Media Contact: Kristin
Comella
13794 NW 4th Street
Suite 212
Sunrise, FL 33325
Telephone 954-835-1500
Email: kcomella@bioheartinc.com
SOURCE Bioheart, Inc.